IPXL News Alert Impax Laboratories (IPXL) 31.32 12/25/2014 1

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Impax Laboratories (IPXL) 31.32 $IPXL

An Upcoming Catalyst At Impax Laboratories
Michael Hagan - at Seeking Alpha - Thu Dec 18, 10:57AM CST

IPXL: 31.32 (+0.26)

Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H1 2014
M2 - Thu Dec 18, 3:29AM CST
Research and Markets (http://www.researchandmarkets.com/research/3j4lzn/attention_deficit) has announced the addition of the "Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD) and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Attention Deficit Hyperactivity Disorder (ADHD) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Attention Deficit Hyperactivity Disorder (ADHD) pipeline depth and focus of Indication therapeutics Companies Mentioned: - DURECT Corporation - Eli Lilly and Company - Dainippon Sumitomo Pharma - Taisho Pharmaceutical - NeuroDerm - Samyang Holdings Corporation - Pfizer - Impax Laboratories - Shire - Collegium Pharmaceutical - Bionomics Limited - Chelsea Therapeutics International - Hisamitsu Pharmaceutical - Theravance - Arbor Pharmaceuticals - Curemark - Supernus Pharmaceuticals - Intra-Cellular Therapies - Tris Pharma - Neos Therapeutics - KemPharm - Otsuka Holdings - Reviva Pharmaceuticals - Amarantus Bioscience Holdings - Mnemosyne Pharmaceuticals - Alcobra - Signature Therapeutics - P2D Bioscience - AbbVie For more information visit http://www.researchandmarkets.com/research/3j...on_deficit
IPXL: 31.32 (+0.26), CHTP: 6.52 (-0.03), SUPN: 8.52 (+0.15), ITCI: 17.99 (+0.16), LLY: 70.16 (+0.42), DRRX: 0.81 (-0.01)

Actavis to Appeal Ruling Regarding Namenda IR Sales - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 16, 5:20PM CST
Actavis plc (ACT) announced its decision to file an emergency appeal for an immediate overturn of the lower court ruling that will require the company to continue selling Namenda IR.
IPXL: 31.32 (+0.26), ACT: 254.20 (-1.68), AKRX: 36.47 (+0.43), MYL: 56.97 (+0.39)

Actavis Likely to Continue Selling Namenda IR Tablets - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Dec 12, 2:20PM CST
Actavis plc (ACT) may face an injunction under which the company will have to continue selling Namenda IR.
IPXL: 31.32 (+0.26), ACT: 254.20 (-1.68), AKRX: 36.47 (+0.43), MYL: 56.97 (+0.39)

First patient enrolled in Acorda Phase 3 PD trial
Seeking Alpha - at Seeking Alpha - Wed Dec 10, 7:06AM CST

IPXL: 31.32 (+0.26), ADMS: 16.10 (+1.45), TEVA: 57.09 (+0.33), ACOR: 39.14 (+0.74), PRTA: 20.14 (+1.41), NDRM: 5.90 (-0.19)

Impax Laboratories Has Returned 21.1% Since SmarTrend Recommendation (IPXL)
Comtex SmarTrend(R) - Fri Dec 05, 5:03PM CST
SmarTrend identified an Uptrend for Impax Laboratories (NASDAQ:IPXL) on October 9th, 2014 at $26.75. In approximately 2 months, Impax Laboratories has returned 21.14% as of today's recent price of $32.40.
IPXL: 31.32 (+0.26)

Migraine - Pipeline Review, H2 2014
M2 - Wed Dec 03, 7:48AM CST
Research and Markets (http://www.researchandmarkets.com/research/xq8n9b/migraine) has announced the addition of the "Migraine - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Migraine, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Migraine and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Migraine - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Migraine pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Ache Laboratorios Farmaceuticos - Alder Biopharmaceuticals - Allergan - Amgen - Astellas Pharma - Avanir Pharmaceuticals - BioDelivery Sciences - Biofrontera - Bristol-Myers Squibb - D-Pharm - Eli Lilly and Company - Heptares Therapeutics - Impax Laboratories - IntelGenx - Istituto Italiano di Tecnologia - Medestea Research & Production - Merck & Co - Nektar Therapeutics - Northern Light Pharmaceuticals - Paladin Labs - Pfizer - Pozen - Proreo Pharma - Questcor Pharmaceuticals - Revance Therapeutics - TheraJect - Transcept Pharmaceuticals - Trigemina - Vertex Pharmaceuticals Incorporated - iCeutica For more information visit http://www.researchandmarkets.com/research/xq8n9b/migraine
VRTX: 115.15 (+1.40), AMGN: 160.67 (+3.15), LLY: 70.16 (+0.42), BMY: 59.15 (-0.01), NKTR: 15.02 (+0.23), AGN: 210.12 (+0.95), IPXL: 31.32 (+0.26), ALDR: 25.67 (+0.43), QCOR: 93.60 (+1.52), MRK: 57.46 (+0.25), TSPT: 1.70 (-0.04), RVNC: 16.65 (+0.42), POZN: 7.86 (+0.07)

Valeant's Onexton Gel Gets FDA Approval for Acne - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 01, 5:30PM CST
Valeant Pharmaceuticals International, Inc.'s (VRX) Onexton Gel received FDA approval for acne vulgaris (including non-inflammatory comedonal and inflammatory acne).
IPXL: 31.32 (+0.26), VRX: 140.33 (-0.22), SCMP: 13.75 (+0.44), ALXN: 181.96 (+3.09), GSK: 42.85 (+0.11)

UCB-Daiichi Sankyo Ink Deal to Sell Vimpat in Japan - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 01, 2:20PM CST
UCB SA (UCBJF) and Daiichi Sankyo have signed a deal to jointly commercialize Vimpat for the treatment of epilepsy in Japan.
IPXL: 31.32 (+0.26), VRX: 140.33 (-0.22), SCMP: 13.75 (+0.44)

Shares of IPXL Up 22.2% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Nov 28, 11:04AM CST
SmarTrend identified an Uptrend for Impax Laboratories (NASDAQ:IPXL) on October 9th, 2014 at $26.75. In approximately 2 months, Impax Laboratories has returned 22.23% as of today's recent price of $32.69.
IPXL: 31.32 (+0.26)

Is Impax Laboratories (IPXL) Stock a Solid Choice Right Now? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Nov 28, 7:57AM CST
Impax Laboratories is one stock that might be an intriguing choice for investors as it is seeing solid earnings estimate revision and has a Zacks Industry Rank of 29
IPXL: 31.32 (+0.26)

Johnson & Johnson's Rezolsta Approved in the EU for HIV-1 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 27, 12:20PM CST
Johnson & Johnson (JNJ) gained EU approval for its HIV-1 drug, Rezolsta.
IPXL: 31.32 (+0.26), AGN: 210.12 (+0.95), JNJ: 104.59 (+0.31), GILD: 91.29 (+1.84)

Insys' Cannabidiol Gets another Orphan Drug Designation - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 25, 9:40AM CST
Insys Therapeutics, Inc.'s (INSY) pharmaceutical cannabidiol (CBD) candidate received orphan drug designation from the FDA for the treatment of pediatric schizophrenia.
IPXL: 31.32 (+0.26), AGN: 210.12 (+0.95), LCI: 42.29 (+1.79), INSY: 41.52 (+0.51)

Supernus Files Trokendi XR Patent Infringement Lawsuit - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 24, 5:00PM CST
Supernus Pharmaceuticals, Inc. (SUPN) filed a patent infringement lawsuit against Zydus accusing the latter of infringement of three patents covering Trokendi XR.
IPXL: 31.32 (+0.26), ACT: 254.20 (-1.68), SUPN: 8.52 (+0.15), MYL: 56.97 (+0.39)

Agios (AGIO) Shares Up on Positive AG-120 Study Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 20, 3:33PM CST
Shares of Agios Pharmaceuticals (AGIO) soared 14.51% after the company reported positive safety and clinical data on pipeline candidate, AG-120, from an ongoing phase I dose escalation study.
IPXL: 31.32 (+0.26), BIIB: 340.89 (+5.13), AGIO: 109.67 (+2.45), CELG: 109.60 (+3.48)

Uptrend Call Working As Impax Laboratories Stock Rises 12.8% (IPXL)
Comtex SmarTrend(R) - Thu Nov 20, 9:27AM CST
SmarTrend identified an Uptrend for Impax Laboratories (NASDAQ:IPXL) on October 9th, 2014 at $26.75. In approximately 1 month, Impax Laboratories has returned 12.84% as of today's recent price of $30.18.
IPXL: 31.32 (+0.26)

Mallinckrodt Q4 Earnings Boosted by Acquisitions, Sales Beat - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 19, 9:07AM CST
Mallinckrodt (MNK) reported adjusted earnings of $1.68 per share in the fourth quarter of fiscal 2014, beating the Zacks Consensus Estimate of $1.34. Earnings were above the year-ago figure of 98 cents per share.
IPXL: 31.32 (+0.26), MNK: 97.84 (-0.29), BIIB: 340.89 (+5.13), MYL: 56.97 (+0.39)

Corium International (CORI) Jumps: Stock Moves 14.3% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Nov 19, 8:25AM CST
Corium International (CORI) was a big mover last session, with shares rising over 14% on the day.
IPXL: 31.32 (+0.26), CORI: 6.00 (-0.44), AKRX: 36.47 (+0.43), MYL: 56.97 (+0.39)

Is Mallinckrodt (MNK) Poised to Beat Q4 Earnings Estimates? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 4:30PM CST
Mallinckrodt plc (MNK) is set to report fourth-quarter fiscal 2014 results on Nov 19.
IPXL: 31.32 (+0.26), MNK: 97.84 (-0.29), BIIB: 340.89 (+5.13), MYL: 56.97 (+0.39)

AxoGen (AXGN) Looks Good: Stock Adds 5.5% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 8:46AM CST
AxoGen (AXGN) was a big mover last session, with shares rising nearly 6% on the day.
IPXL: 31.32 (+0.26), AXGN: 3.85 (+0.17), AKRX: 36.47 (+0.43), MYL: 56.97 (+0.39)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Lieda Shadwick’s Career Education Work Earns 2026 Honor

Updated Category News Views 66

Twenty-six years in classrooms is not the sort of accomplishment that needs fireworks to carry weight. Lieda A. Shadwick’s recognition as The Inner Circle’s 2026 Educator of the Year points to a career built around a stubbornly important idea: students need more than academic vocabulary if they are going to navigate work, leadership, and business with any confidence....

Continue Reading
Five SEAL Medal of Honor Signatures, One Charity Lot

Updated Category News Views 58

A single rifle can carry a staggering amount of meaning when the names on it belong to all five living U.S. Navy SEAL Medal of Honor recipients. Rock Island Auction Company plans to offer that one-of-a-kind custom precision rifle during its December 4–6, 2026 Premier Firearms Auction, and the financial arrangement is unusually clean: 100% of proceeds are slated for the...

Continue Reading
AI Forces Learning Teams to Redefine Their Core Job

Updated Category News Views 73

Training Departments Are Not Sitting Still Corporate learning has spent years being treated like the office instruction manual, and AI is making that old arrangement look awfully flimsy. RedThread Research's November 19, 2026 study lands on a point that ought to make senior management pay attention: learning and development leaders are not merely waiting around to be...

Continue Reading
Botanica’s Illuminations Carries More Than Holiday Glow

Updated Category News Views 74

Two million lights are doing more than brightening up a few winter evenings in Wichita. Illuminations at Botanica returns from November 23, 2026, through January 2, 2027, and the pleasant part of this story is that the spectacle has a practical backbone: it is Botanica’s largest fundraiser. For a garden nonprofit, that matters a whole lot more than another shiny...

Continue Reading
Movement Elevates a Longtime Insider as Its New CEO

Updated Category News Views 81

Chalk dust rarely makes headlines, yet this is the sort of leadership change that can decide whether a consumer brand keeps its footing. Movement Climbing, Yoga and Fitness named Ryan Sewell chief executive officer effective November 18, 2026, with Anne-Worley Moelter moving into the chairperson role. It is a conspicuously internal handoff: Sewell started at the Boulder...

Continue Reading
LKQ’s Europe ERP Mess Turns Into a Credibility Test

Updated Category News Views 80

A software rollout should not be able to punch a company in the teeth twice, yet LKQ shareholders have watched precisely that ugly movie in 2026. The October 23 disclosure was a real gut-check: an immediate CEO departure, a $16 million net loss, and renewed acknowledgement that the German enterprise-resource-planning rollout was disrupting Europe. Shares fell $5.05, or...

Continue Reading
Nvidia Faces SEC Probe Report and New Lawsuit Stakes

Updated Category News Views 187

Silicon Valley's favorite growth machine has stumbled into the sort of fog investors hate most: regulatory questions, leadership upheaval, and a stock-price reaction with no clean answer attached. Reports cited in the lawsuit update say the Securities and Exchange Commission has opened a civil probe into NVIDIA's investor disclosures following former CEO Jensen Huang's...

Continue Reading
Live Nation Tests Creator Content With Morgan Jay Series

Updated Category News Views 135

A comedian turning crowd work into songs is hardly a boardroom event, but this one has a useful wrinkle: Live Nation Studios put financing behind it. Morgan Jay and Austin-based agency Hello Party launched Music Therapy with Morgan Jay on YouTube on November 18, with Kam Patterson opening the season. The show pairs Jay and celebrity guests for loose conversation,...

Continue Reading
NYSE Message Record Puts Market Plumbing Into Focus

Updated Category News Views 120

A trillion messages is not a cute little exchange statistic; it is the sort of number that tells you whether the market’s pipes can keep working when everybody starts shouting at once. NYSE says it handled a record 1.166 trillion messages in one day on November 5, roughly 4% above the prior high set amid April 2025 volatility. Better yet, according to the exchange,...

Continue Reading
First Grade Literacy Push Deserves a Harder Look Now

Updated Category News Views 138

A reading gap can become a concrete wall before anyone bothers measuring it. That is the uncomfortable point behind Ignite Reading's First Grade Promise, and it deserves more attention than another polished education announcement usually gets. At a Nov. 5 Convene 2026 gathering in Boston, 56 district and literacy leaders from six states focused on getting children reading...

Continue Reading

Top 5 Most Recently Viewed Articles

Nabors Industries Expands Reach with Parker Wellbore Buyout

Updated Category News Views 205

Nabors Industries Completes Acquisition of Parker Wellbore Nabors Industries Ltd. (NYSE: NBR) has officially concluded its acquisition of Parker Wellbore, a strategic move that strengthens Nabors' leadership in drilling and associated value-added services. This acquisition not only cements Nabors' robust market position but also enhances its service capabilities across...

Continue Reading
Utz, Integer, Arcosa, Dominion: Fair Deals for Shareholders?

Updated Category News Views 18

Investor Concerns Over Recent M&A Deals Today, you can't shake a stick without hitting some M&A news and, frankly, these deals with Utz, Integer, Arcosa, and Dominion have got investors squirming in their seats. With insiders possibly raking in the dough, shareholders are left wondering if they’re just getting table scraps. And you know what makes folks justifiably...

Continue Reading
Revolutionizing Business Growth with QuickBooks AI Tools

Updated Category News Views 151

Revolutionizing Business Growth with QuickBooks AI Tools Software Experts recently spotlighted QuickBooks for its innovative approach in transforming business financial forecasting and planning. The introduction of AI-driven agents in QuickBooks signifies a major transition towards more connected and automated financial management, streamlining processes while enhancing...

Continue Reading
CMB Certification: A New Era for Sustainable Wellness Brands

Updated Category News Views 234

CMB Certification: Pioneering a Path for Wellness Brands Crunchy Mama Box (CMB) has recently unveiled its CMB Certification Program, an initiative that aims to validate wellness brands dedicated to sustainability, ethical practices, and social contributions. This certification serves as a valuable tool for consumers, empowering them to make well-informed decisions while...

Continue Reading
Prevounce Health Integrates AI for Enhanced Patient Care Solutions

Updated Category News Views 303

Prevounce Health Enhances Remote Care with Innovative AI Insights Prevounce Health has recently unveiled an exciting feature that integrates artificial intelligence into its remote care management offerings. This initiative aims to provide AI-generated summaries and personalized recommendations for patients enrolled in remote care management programs, transforming the...

Continue Reading